Project Title

A study of Zanubrutinib versus Lenalidomide in participants with relapsed/refractory follicular or marginal zone lymphoma

Official Title

A phase 3 randomized, open-label multicenter study of Zanubrutinib (BGB-3111) plus anti-CD20 antibodies versus Lenalidomide plus Rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma.

Project Summary

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.

Blood Disorder

• Relapsed/Refractory Follicular Lymphoma
• Marginal Zone Lymphoma

Patient Recruitment Details

Patient recruitment status: open

Number of patients (Globally)

750